secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-062421
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q4 revenue $196M (+65% YoY); AXS-05 PDUFA set for April 30, 2026
-----------------------------------------------------------------------

- Total net product revenue Q4 $196.0M, FY $638.5M (+66% YoY); AUVELITY sales $507.1M (+74%).
- Net loss Q4 $28.6M ($0.56/share), FY $183.2M ($3.68); cash $322.9M; operating loss narrowed.
- sNDA for AXS-05 (Alzheimer's agitation) granted Priority Review, PDUFA target April 30, 2026.
- SUNOSI generic patent litigation with Alkem settled; license delays generic entry until 2040.
- Acquired AXS-17 (GABA A PAM) for epilepsy; NDA submission for AXS-12 narcolepsy expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/0001193125-26-062421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-062421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer